Yarrow Bioscience (formerly VYNE Therapeutics) has completed its merger and will begin trading on Nasdaq under 'YARW'. The company is advancing its lead drug candidate, YB-101, for Graves' disease and thyroid eye disease, with key data readouts expected in 2H 2027.
This filing announces the completion of the merger between Yarrow Bioscience and VYNE Therapeutics, with the combined entity operating as Yarrow Bioscience and trading on Nasdaq under 'YARW'. This is a significant corporate event, marking the public debut of a new biotech company with a specific drug pipeline. The market impact is high due to the new listing and the outlined development timeline for YB-101, a potential first-in-class treatment for Graves' disease and thyroid eye disease. Short-term, investors will be watching the initial trading performance of YARW. Long-term, the company's valuation will be heavily influenced by the upcoming Phase 2a/2b data for GD and Phase 1 MAD data for TED in 2H 2027, presenting both a key opportunity and risk for traders.